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Pancreatic cancer is one of the most lethal malignant diseases in gastrointestinal system that only about 15-20% of 
the patients are potential candidates for resection at diagnostic stage. However, with the advent of neoadjuvant chemo-
therapy and advancement of surgical skills, patients with locally advanced pancreatic cancer (LAPC), which were 
deemed initially unresectable, have undergone margin negative radical resection. Here, we present a case of a patient 
with LAPC who was previously treated with neoadjuvant FOLFIRINOX and underwent pancreaticoduodenectomy com-
bined with vascular resection after preoperative percutaneous transhepatic portal vein stent placement to relieve of 
portal vein obliteration. The patient recovered without any complication and was discharged on day 8 postoperatively. 
(Ann Hepatobiliary Pancreat Surg 2020;24:551-556)
Key Words: Locally advanced pancreatic cancer; Neoadjuvant chemotherapy; Portal vein stent
Received: April 17, 2020; Revised: June 15, 2020; Accepted: June 17, 2020
Corresponding author: Chang Moo Kang
Department of Surgery, Yonsei University College of Medicine, Ludlow Faculty Research Building #201, 50 Yonsei-ro, Seodaemun-gu, Seoul
03722, Korea
Tel: +82-2-313-8289, Fax: +82-2-2228-2135, E-mail: cmkang@yuhs.ac
Copyright Ⓒ 2020 by The Korean Association of Hepato-Biliary-Pancreatic Surgery
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Annals of Hepato-Biliary-Pancreatic Surgery ∙ pISSN: 2508-5778ㆍeISSN: 2508-5859
INTRODUCTION
Pancreatic cancer is one of the most lethal malignant 
diseases in gastrointestinal system. Margin-negative pan-
createctomy followed by adjuvant chemotherapy is the 
most effective modality in treating pancreatic cancer.1-3 
However, at diagnostic stage, potential candidates for re-
section are about 15-20% and the rest are locally ad-
vanced or metastatic stage of cancer. Currently, neoadju-
vant chemotherapy has been introduced to improve onco-
logic outcomes by increasing margin-negative resection 
rates, decreasing lymph node invasion, and providing an 
early treatment of micro-metastatic disease.4 In addition, 
advancement of surgical technique and perioperative man-
agement made radical pancreatectomy with combined ve-
nous vascular resection safe and effective in managing ad-
vanced pancreatic cancer.5
Pancreatic head cancer with portal vein (PV) ob-
literation has several important clinical issues to consider. 
First, pancreatic cancer invading portal vein may extend 
even to the superior mesenteric artery. Therefore, biologi-
cal behavior is expected to be very aggressive. Second, 
pancreaticoduodenectomy (PD) with combined superior me-
senteric vein-splenic vein-portal vein (SMV-SV-PV) con-
fluence and vascular reconstruction using direct end-to- 
end anastomosis or interposition graft should be prepared. 
If vascular reconstruction is technically impossible, this 
condition should be regarded as unresectable, or locally 
advanced pancreatic cancer. Third, development of secon-
dary collateral vessels to maintain mesentero-hepatic flow 
may result in massive bleeding during dissection. In addi-
tion, sequential disconnection of potential collateral ves-
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Fig. 1. Preoperative image study and PTPVS insertions. Endoscopic biliary drainage tube and periportal cavernous transformation 
(thin white arrows) due to total obliteration of portal vein by the tumor (*) are noted (A and C). Common hepatic artery and 
gastroduodenal artery invasion is highly suspected (thick black arrow, B). Preoperative PTPVS was inserted. Note that periportal 
collateral vessels (thin white arrows, D) all disappeared immediately after successful PTPVS (E). Preoperative 3-dimensional 
arterial reconstruction can be helpful when designing the surgical strategy. Portal vein stent can be identified with endoscopic 
biliary drainage tube.
sels during the surgical procedure could result in severe 
venous congestion and secondary edematous change in 
small intestines, probably providing adverse impact on 
subsequent pancreaticojejunostomy (PJ), or hepaticojejuno-
stomy (HJ), and overall postoperative recovery outcomes. 
Therefore, determining accurate preoperative assessment 
of tumor extent, and appropriate management to decom-
press the portal vein pressure is mandatory for safe and 
effective curative pancreatectomy in pancreatic cancer with 
PV obliteration.
Here, we present a case of successful radical pancrea-
tectomy after preoperative percutaneous transhepatic por-
tal vein stent (PTPVS) in pancreatic head cancer with ob-
literated portal vein following neoadjuvant chemotherapy. 
This is thought to be the first official report in managing 
pancreatic cancer surgery in Korea using the PTPVS 




A 46-year-old male was admitted the hospital due to 
jaundice and abdominal discomfort in January, 2019. 
Blood laboratory results showed elevated AST (120 IU/L; 
normal: 13.0-34.0 IU/L), ALT (128 IU/L; normal: 5.0- 
46.0 IU/L), total bilirubin (7.9 mg/dl; normal: 0.5-1.8 mg/ 
dl), direct bilirubin (6.2 mg/dl; normal: 0.1-0.4 mg/dl), 
and gamma-GT (1591 IU/L; normal: 12.0-54.0 IU/L). Tumor 
markers CEA (24.8 ng/ml; normal: 0-5 ng/ml) and CA19-9 
(3132.0 U/ml; normal: 0-34 U/ml) were both elevated. 
Radiologic evaluation (CT scan) showed a pancreatic head 
cancer 3.5 cm in size, invading the common bile duct 
(CBD) and duodenum with biliary dilatation, and also in-
vading the gastroduodenal artery (GDA), portal vein (PV), 
and superior mesenteric vein (SMV) with encasing the 
SMV. Endoscopic ultrasonography (EUS) found a 4 cm- 
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Fig. 2. Operative view and sur-
gical specimens. Grossly margin- 
negative resection was performed. 
Note the arterial (long thin white 
arrow) and portal vein (short 
thin white arrow) reconstruction 
(A). Surgical specimen is excised 
en-bloc (B). Note the combined 
resection of common hepatic ar-
tery-gastroduodenal artery-proper 
hepatic artery confluence (red 
colored vessel-loop, C) and seg-
ment of PV with PTPVS (blue 
colored vessel-loop, D).
sized solid mass invading the distal CBD with upstream 
dilatation. EUS-fine needle aspiration was done and was 
reported poorly differentiated adenocarcinoma. An endo-
scopic retrograde bile drainage (ERBD) catheter was in-
serted.
Under the diagnosis of locally advanced pancreatic can-
cer (cT4N1, Stage III), the patient was directed to sys-
temic chemotherapy and went through 16 cycles of 
FOLFIRINOX and combined chemoradiotherapy (CCRT) 
using Capecitabine+6000 cGy in 25 fractions in between 
the 12th and 13th cycle. While assessing resectability after 
neoadjuvant treatment, the cancer did not seem to have 
progressed and the disease status was stable. Preoperative 
last CA 19-9 and CEA level were noted to be 671 U/ml 
and 11.5 ng/ml, respectively. The patient’s general con-
dition was quite acceptable. Surgical resection was con-
sidered as neither systemic metastasis nor disease pro-
gression were noted during neoadjuvant treatment. How-
ever, vascular invasions were still noted. Especially, a 
short segment of common hepatic artery (CHA)-gastroduo-
denal artery (GDA)-proper hepatic artery (PHA) con-
fluence looked invaded and portal vein total obliteration 
with secondary periportal engorged collateral vessels was 
observed (Fig. 1A-C). Superior mesenteric artery (SMA) 
and proximal part of CHA were spared. In order to reduce 
intraoperative portal vein pressure and potential risk of se-
vere intraoperative bleeding, mesenteric congestion, and 
hepatic ischemia, preoperative percutaneous transhepatic 
portal vein stent (PTPVS) was placed on March, 10th, 
2020 (Fig. 1D-F).
Operative findings
On March, 25th, 2020, exploratory laparotomy was 
performed. During the operation, severe adhesion around 
the pancreatic neck portion and celiac axis was observed. 
After careful dissection and isolation, total pancreatec-
tomy with splenectomy and combined resection of com-
mon hepatic artery and SMV-SV-PV confluence with end- 
end vascular reconstruction was performed (Fig. 2). Total 
pancreatectomy instead of PD with pancreatic head exci-
sion was done considering the severe atrophic change of 
the whole pancreas. The operation time was 7.5 hours 
with estimated blood loss of 1100 ml. No transfusion was 
given. 
Postoperative course and pathological 
examination
The postoperative recovery was smooth without com-
plications. Postoperative liver function test improved over 
time (Fig. 3). Follow-up blood CEA and CA 19-9 level 
on postoperative day seven were 2.55 ng/ml and 172.0 
U/ml, respectively. The patient was discharged on the 8th 
day after surgery under regular insulin therapy. It was re-
ported that the residual tumor was of moderate differ-
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Fig. 3. Postoperative changes of 
liver function test.
entiation with extracellular mucin formation, showing par-
tial response to chemotherapy (Modified Ryan Scheme for 
tumor regression score 2). The size of the tumor was 
3.5×3.5×2.2 cm (ypT2) with lymphovascular and peri-
neural invasion. Excised SMV-SV-PV confluence showed 
invasion of carcinoma while hepatic artery was free of 
carcinoma. All resection margins were free from carcinoma. 
Two lymph nodes out of 12 showed metastatic carcinoma 
(ypN1).
After discharge, the patient came back for follow up 
visits during which he was treated for ascites and adjuvant 
chemotherapy is currently being planned at 6 week point 
of operation.
DISCUSSION
Percutaneous transhepatic portal vein stent (PTPVS) is 
usually applied to portal vein stenosis due to cancer re-
currence, change after pancreaticobiliary cancer surgery, 
or liver transplantation.6-9 PTPVS is regarded as accept-
able minimally invasive approach due to high success rate 
with low complications.10,11 Curative intent pancreatec-
tomy may not be an indication when venous involvement 
is related to PV occlusion with periportal collaterals be-
cause there is significant risk of intraoperative bleeding 
and ischemic injury to the liver and bowels during the 
operation. In fact, in order to resolve these issues, Nakao 
et al.12 and Nakao and Takagi13 used antithrombogenic 
catheter bypass to reduce the PV pressure, and Bachellier 
et al.14 performed an intraoperative mesentericoportal shunt 
for pancreatic resection for LAPC with PV occlusion and 
portal hypertension, which all require additional special-
ized surgical instruments and vascular techniques leading 
to surgical complexity and prolongation of operation time. 
The present case demonstrated preoperative PTPVS can 
play an important role in reducing intraoperative risk as-
sociated with PV occlusion in well selected pancreatic 
cancer. Considering that neoadjuvant chemotherapy be-
came the standard in borderline and locally advanced pan-
creatic cancer,15 this strategy can be thought to have ex-
panded the chance of curative pancreatectomy even in ad-
vanced pancreatic cancer, following neoadjuvant chemo-
therapy. Till now, only a few cases of preoperative PTPVS 
followed by pancreatectomy have been reported.16 Recent-
ly, Alden et al.17 reported PD following PTPVS in 15 pa-
tients with locally advanced pancreatic cancer (about 68% 
of resectability, 15 out of 22 patients) without perioper-
ative mortality. In addition, survival differences were also 
observed between surgically resected group and non-re-
sected group (17 months vs. 9 months, p=0.0422), sug-
gesting this approach can be a potentially beneficial way 
for surgical resection in patients with PV, and SMV 
occlusion.
According to the current experience, followings are po-
tential advantages of preoperative PTPVS in pancreatic 
cancer surgery. First, preoperative PTPVS makes surgical 
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procedure simple without having to prepare for a complex 
intraoperative meso-systemic shunt. Second, the pre-
operative cavernous transformation around PV is dimin-
ished and can reduce the chance of intraoperative severe 
bleeding. Third, in spite of sequential disconnection of 
veins draining to SMV and PV, there was no small bowel 
congestion and hepatic ischemia due to maintenance of 
mesentero-hepatic flow by the PTPVS.
In the past, Fortner18 proposed a regional pancreatec-
tomy for obtaining a wide tissue margin with regional 
lymphatic clearance in 1973, but pancreatectomy with ex-
tensive lymphadenectomy19 and combined vascular re-
section, especially, arterial resection have not been ac-
tively recommended in managing pancreatic cancer.20 
Introduction of potent chemotherapeutic agents1,3,21 and 
advanced surgical techniques for vascular reconstruction 
thanks to liver transplantation are thought to be making 
a paradigm shift from conservative surgical approach to 
aggressive radical surgery again in well selected advanced 
pancreatic cancer. In addition, oncologic concept of total 
mesopancreas excision22 has been introduced to control 
local spread of pancreatic cancer. The oncologic signifi-
cance of mesopancreas concept is still controversial, but 
it is expected to play a significant role for margin-neg-
ative resection in well-selected advanced pancreatic can-
cer following neoadjuvant treatment. 
As Fortner23 commented, “It is apparent that there is 
a very strong basis for the belief that regional pancreatec-
tomies (=aggressive pancreatic cancer surgery, interpreted 
by authors) will result in significantly increased cure rates”, 
It is true that pancreatic cancer survival is still dismal, 
however, long-term oncologic outcomes of resected pan-
creatic cancer will be optimistic in the near future due to 
integrated impact of perioperative multidisciplinary ap-
proach, potent chemotherapy, and advanced surgical tech-
nique for margin-negative resection. We never give up.
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